Application of alpha-lipoic acid in preparation of medicine for treating pulmonary fibrosis
By using α-lipoic acid to reduce ferrodysfunction levels and inhibit TGF-β1-induced pulmonary epithelial and fibroblast transformation, the high cost and safety problems of TGF-β1-induced pulmonary fibrosis therapy in the prior art were solved, and the high cost and safety of TGF-β1-induced pulmonary fibrosis therapy was achieved. Effective treatment and prevention of pulmonary fibrosis.
Patent Information
- Application Number
- CN202411252865.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to provide a low-cost, safe and effective drug for treating TGF-β1-induced pulmonary fibrosis. Current drugs such as pirfenidone and nidanib are toxic and cost-effective, long-chain non-coding RNA and Huashan The safety and effectiveness of the parameters have not been fully determined.
Using α-lipoic acid as a drug for treating TGF-β1-induced pulmonary fibrosis, inhibits the transformation of lung epithelial cells into mesenchymal cells and fibroblasts into myofibroblasts, reducing the deposition of extracellular matrix by reducing ferrodysfunction levels .
α-lipoic acid significantly inhibits TGF-β1-induced pulmonary fibrosis at the ex vivo cell level, is non-toxic and has good safety, is low in cost, and has the potential for widespread promotion and application.
Smart Images

Figure CN119074723A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pulmonary fibrosis drugs and relates to the application of alpha-lipoic acid in preparing a drug for treating TGF-β1-induced pulmonary fibrosis. Background Art
[0002] Pulmonary fibrosis is a refractory and irreversible progressive pulmonary fibrosis disease with unknown etiology. Its typical pathological features are repeated local micro-injuries of the alveolar epithelium, which trigger abnormal epithelial-mesenchymal transition (EMT) and excessive proliferation and differentiation of fibroblasts. EMT is a process in which fully differentiated epithelial cells gradually transform into mesenchymal cells under the influence of external factors and lose the original functions of epithelial cells. The decrease of epithelial marker E-cadherin and the increase of mesenchymal markers N-cadherin, vimentin and alpha smooth muscle actin (α-SMA) are considered to be the signs of EMT. Fibroblasts are the main effector cells of pulmonary fibrosis. In a profibrotic environment, epithelial cells differentiate into fibroblasts through the EMT process. Mechanical tension and inflammatory response after injury cause fibroblasts to gather from the peri-injury area and transform into primitive myofibroblasts. Under the action of cytokines, they further transform into myofibroblasts and continue to proliferate, leading to scar formation and a large amount of abnormal deposition of extracellular matrix (ECM). The increase of type I collagen (Collagen I), fibronectin 1 (FN1) and α-SMA, the main components of ECM, promotes the progression of pulmonary fibrosis and sclerosis of lung tissue, and ultimately leads to pulmonary dysfunction, which seriously damages the health and quality of life of patients. The median survival time of patients is only 2.5 to 3.5 years, and the five-year survival rate is about 20%.
[0003] Although the anti-fibrotic drugs pirfenidone and nintedanib have been approved for the clinical treatment of pulmonary fibrosis, their toxicity and poor prognosis make the disease a pressing medical problem. Non-drug treatments for pulmonary fibrosis include oxygen therapy, mechanical ventilation, and lung transplantation, which are expensive and cannot effectively alleviate disease progression and the frequency of acute exacerbations. Therefore, it is of great significance to find a low-cost, safe and effective drug for the treatment of pulmonary fibrosis.
[0004] TGF-β1 is the most core and effective cytokine that mediates pulmonary fibrosis. It can be produced by a variety of cells, including lymphocytes, monocytes, epithelial cells, and fibroblasts. It induces the occurrence of pulmonary fibrosis by inducing the aggregation of inflammatory cells, activating monocytes and pulmonary fibroblasts, promoting EMT, the recruitment of fibroblasts, the differentiation and proliferation of myofibroblasts, and ECM deposition. Therefore, as a current research hotspot and important drug target for pulmonary fibrosis, research focusing on TGF-β1 is of great significance for the prevention and treatment of pulmonary fibrosis.
[0005] At present, some technical solutions for treating TGF-β1-induced pulmonary fibrosis have been disclosed. For example, document 1 (lncSIL negatively regulates TGF-β1-induced alveolar epithelial cell-mesenchymal transformation through the EZH2 / P21 / CDK6 signaling pathway [J]. Journal of Anhui Medical University, 2024, No. 4: 600-604) discloses a substance for treating idiopathic pulmonary fibrosis, lncSIL, which inhibits the cell cycle process by negatively regulating the EZH2 / P21 / CDK6 signaling pathway and thus inhibits the transformation of TGF-β1-induced alveolar epithelial cells to mesenchymal cells. However, as a long non-coding RNA, this substance has the characteristics of rich candidate targets and wide distribution of indications, and it is difficult to ensure its safety and effectiveness. Another document 2 (Regulation of in vitro fibrosis by Panax notoginseng through the TGF-β1 / Smad3 pathway [J]. Journal of Tianjin University of Traditional Chinese Medicine, 2024, No. 6: 523-530) discloses a drug for treating pulmonary fibrosis, Panax notoginseng, which can inhibit collagen deposition in mouse embryonic fibroblasts induced by TGF-β1. However, as a natural Chinese herbal medicine, the composition of this substance is relatively complex, and its effective ingredients for anti-pulmonary fibrosis have not yet been determined. Therefore, it is necessary to explore a low-cost, safe and effective drug for the treatment of TGF-β1-induced pulmonary fibrosis. Summary of the invention
[0006] The purpose of the present invention is to solve the above problems existing in the prior art and provide an application of α-lipoic acid in the preparation of a drug for treating TGF-β1-induced pulmonary fibrosis. The present invention clarifies the effect and specific mechanism of action of α-lipoic acid in the treatment of TGF-β1-induced pulmonary fibrosis, and provides a new drug for treating and preventing TGF-β1-induced pulmonary fibrosis.
[0007] To achieve the above object, the technical solution adopted by the present invention is as follows:
[0008] The invention discloses an application of alpha-lipoic acid in preparing a medicine for treating pulmonary fibrosis, wherein the pulmonary fibrosis is pulmonary fibrosis induced by TGF-β1.
[0009] Lipoic acid is an octahedral disulfide containing a chiral center and an asymmetric carbon, so it can produce two optical isomers: (R)-isomer and (S)-isomer. It has good preventive and therapeutic effects on diabetes and metabolic syndrome, central nervous system diseases, cardiovascular diseases, etc. In recent years, the role of lipoic acid in lung diseases has attracted increasing attention. For example, the literature (Experimental study on the intervention of lipoic acid in acute paraquat poisoning-induced pulmonary fibrosis in rats [J]. Chinese Journal of Clinical Physicians (Electronic Edition), 2013, Issue 4: 1620-1621.) disclosed that lipoic acid can alleviate collagen deposition in rat lung tissue caused by paraquat. At the same time, the expression of TGF-β1 in rat lung tissue was detected. After the addition of lipoic acid, TGF-β1 was significantly reduced. Based on the changes in TGF-β1 and lung tissue morphology and collagen, it was speculated that the mechanism of action of lipoic acid may be related to TGF-β1, but it is not clear which specific configuration plays the main role; for example, the literature (Alpha-lipoic acid attenuates silica-induced pulmonary fibrosis by improving mitochondrial function via AMPK / PGC1αpathway activation in C57BL / 6J mice[J].ToxicologyLetters,2021,350:121-132.) discloses that alpha-lipoic acid (R-configured lipoic acid) improves mitochondrial function in mice by activating the AMPK / PGC1α pathway and delays the progression of silica-induced pulmonary fibrosis; for example, the literature (The protective potential of alpha lipoic acid on amiodarone-induced pulmonary fibrosis and hepatic injury in rats[J].Molecular and Cellular Biochemistry,2021,476(9):3433-3448.) discloses that alpha-lipoic acid can reverse amiodarone-induced oxidative stress, inflammation, and fibrosis parameters including TGF-β1 content in serum, and improve pathological damage to the lungs and liver. However, there is no report on whether TGF-β1 is a target for alpha-lipoic acid to treat pulmonary fibrosis. The present invention is the first to explore whether α-lipoic acid can be used to improve TGF-β1-induced pulmonary fibrosis and its mechanism of action, which is of great significance for its application in the prevention and treatment of pulmonary fibrosis.
[0010] Based on the existing technology, it is not known that α-lipoic acid can be used to treat TGF-β1-induced pulmonary fibrosis. Although the literature (Experimental study on the intervention of lipoic acid in acute paraquat poisoning-induced pulmonary fibrosis in rats [J]. Chinese Journal of Clinical Physicians (Electronic Edition), 2013, Issue 4: 1620-1621.) mentioned that the addition of lipoic acid can reduce the expression of TGF-β1, on the one hand, it did not confirm that lipoic acid does improve pulmonary fibrosis by regulating the expression of TGF-β1, and on the other hand, the lipoic acid and α-lipoic acid used in the literature did not improve pulmonary fibrosis by regulating the expression of TGF-β1. They are not exactly the same substances. There are certain differences in structure and performance. Lipoic acid is a racemic body, containing equal proportions of R-configuration lipoic acid and S-configuration lipoic acid, with a lower melting point. It is mainly used as an antioxidant to help eliminate free radicals, while α-lipoic acid is mainly R-configuration lipoic acid, with a higher melting point and biological activity. In addition to anti-oxidation, it can also improve diabetic symptoms, such as stabilizing blood sugar and protecting nerve tissue, reducing nerve damage. Therefore, it cannot be concluded that α-lipoic acid can be used to treat TGF-β1-induced pulmonary fibrosis;
[0011] Although the literature (Effect of ALA on the Expression of TGF-β1 and CTGF in Renal Tissue of STZ-induced DN Rats [J]. Journal of Tongji University (Medical Edition), 2011, (Issue 6).) mentioned that ALA (i.e., α-lipoic acid) can downregulate TGF-β1 in renal tissue, the full text only detected the expression of fibrosis-related indicators TGF-β1 and CTGF by immunohistochemistry, without other fibrosis-related indicators, which cannot indicate that α-lipoic acid can alleviate renal fibrosis, let alone that α-lipoic acid can alleviate TGF-β1-induced renal fibrosis. Since TGF-β1-induced renal fibrosis is not equivalent to TGF-β1-induced pulmonary fibrosis, it cannot indicate that α-lipoic acid can alleviate TGF-β1-induced pulmonary fibrosis;
[0012] Although the literature (Protective effect of α-lipoic acid on the kidneys of diabetic rats and its possible mechanism [J]. Chinese Journal of Modern Medicine, 2018, (Issue 10).) mentioned that α-lipoic acid can inhibit the TGF-β1 signaling pathway and reduce extracellular matrix deposition, it can only indicate that α-lipoic acid can alleviate renal fibrosis in diabetic rats, but cannot indicate that α-lipoic acid can alleviate TGF-β1-induced renal fibrosis. Since TGF-β1-induced renal fibrosis is not equivalent to TGF-β1-induced pulmonary fibrosis, it cannot indicate that α-lipoic acid can alleviate TGF-β1-induced pulmonary fibrosis;
[0013] Although the literature (Study on the Effect of α-lipoic acid on Renal Fibrosis in Rats with Diabetic Nephropathy [J]. Journal of Liaoning Medical College, 2011, (Issue 6).) mentioned that α-lipoic acid exerts its anti-fibrotic effect by inhibiting the expression of TGF-β1 and CTGF in renal tissue, the entire article only detected the expression of TGF-β1 and CTGF proteins in the renal tissue of diabetic rats by protein immunoblotting (Western blot), and there were no other fibrosis-related indicators. The fact that α-lipoic acid alone alleviated the expression of TGF-β1 and CTGF in the renal tissue of diabetic rats with diabetic nephropathy does not mean that α-lipoic acid can alleviate renal fibrosis, let alone that α-lipoic acid can alleviate TGF-β1-induced renal fibrosis. Since TGF-β1-induced renal fibrosis is not equivalent to TGF-β1-induced pulmonary fibrosis, it does not mean that α-lipoic acid can alleviate TGF-β1-induced pulmonary fibrosis.
[0014] As the preferred technical solution:
[0015] As described above, α-lipoic acid is used in the preparation of drugs for treating pulmonary fibrosis. TGF-β1-induced pulmonary fibrosis involves the transformation of pulmonary epithelial cells to mesenchymal cells (EMT) and the transformation of pulmonary fibroblasts to myofibroblasts. These two processes together promote the production of a large amount of extracellular matrix (ECM).
[0016] As described above, in the application of α-lipoic acid in the preparation of a drug for treating pulmonary fibrosis, the lung epithelial cells are human lung epithelial cells A549 or mouse lung epithelial cells MLE-12, and during the transformation of lung epithelial cells to mesenchymal cells, the mRNA and protein expression of E-cadhein in human lung epithelial cells A549 or mouse lung epithelial cells MLE-12 decreases, and the mRNA and protein expression of N-cadherin, Vimentin and α-SMA increase; the lung fibroblasts are human lung fibroblasts MRC-5 or primary lung fibroblasts PMLFs of neonatal rats, and during the transformation of lung fibroblasts to myofibroblasts, the mRNA and protein expression of Collagen I, α-SMA and FN1 in human lung fibroblasts MRC-5 or primary lung fibroblasts PMLFs of neonatal rats increase; the lung epithelial cells may also be other lung epithelial cells, and the lung fibroblasts may also be other lung fibroblasts, and the present invention only lists some of them as examples.
[0017] As described above, the use of α-lipoic acid in the preparation of a drug for treating pulmonary fibrosis, α-lipoic acid inhibits the transformation of lung epithelial cells into mesenchymal cells and the transformation of lung fibroblasts into myofibroblasts by reducing the level of ferroptosis.
[0018] Beneficial effects:
[0019] (1) The present invention constructs a TGF-β1-induced pulmonary fibrosis model at the in vitro cell level, and proves that the drug for treating pulmonary fibrosis prepared by using α-lipoic acid inhibits the transformation of pulmonary epithelial cells into mesenchymal cells and fibroblasts into myofibroblasts by reducing the level of ferroptosis, reduces ECM deposition, treats and prevents TGF-β1-induced pulmonary fibrosis, and has good clinical application prospects;
[0020] (2) The drug for treating pulmonary fibrosis prepared by using α-lipoic acid in the present invention is non-toxic to human and mouse lung epithelial cells and fibroblasts and has good safety;
[0021] (3) Compared with the current anti-fibrotic drugs pirfenidone, nintedanib, long non-coding RNA, and Panax notoginseng, α-lipoic acid has a low cost. Drugs for treating pulmonary fibrosis prepared using α-lipoic acid are conducive to widespread promotion and application. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The figure is a cell viability test result diagram of α-lipoic acid (hereinafter referred to as ALA) treatment groups 1 to 16 and control groups 1 to 4 in Example 1. The data are expressed in the form of mean ± standard error (Mean ± SEM). The number of repeated cases in each group is 6 (n=6). ** indicates that the difference is extremely significant compared with the control group (P<0.01); wherein, Figure 1 Middle A corresponds to ALA-treated groups 1 to 4 and control group 1; Figure 1 Middle B corresponds to 9 to 12 in the ALA-treated group and 3 in the control group; Figure 1 Middle C corresponds to ALA-treated groups 5 to 8 and control group 2; Figure 1 Middle D corresponds to 13 to 16 in the ALA-treated group and 4 in the control group;
[0023] Figure 2 The results of the mRNA expression level detection of the target gene in the cells of the experimental groups 1 to 2, the control groups 1 to 2, the TGF-β1 modeling groups 1 to 2, and the ALA treatment groups 1 to 2 in Example 1 are shown in the form of mean ± standard error (Mean ± SEM), and the number of repeated cases in each group is 4 (n = 4). * and ** respectively indicate significant differences (P < 0.05) and extremely significant differences (P < 0.01) compared with the control group; wherein, Figure 2 A in the middle corresponds to experimental group 1, control group 1, TGF-β1 modeling group 1, and ALA treatment group 1; Figure 2 B in the middle corresponds to experimental group 2, control group 2, TGF-β1 modeling group 2, and ALA treatment group 2; in the genes of each project, from left to right, they correspond to the control group, TGF-β1 modeling group, ALA treatment group, and experimental group;
[0024] Figure 3The results of the protein expression level detection of E-cadherin in the cells of the experimental group 1, the control group 1, the TGF-β1 modeling group 1, and the ALA treatment group 1 in Example 1 are shown in the form of Mean±SEM (n=3), **P<0.01);
[0025] Figure 4 The results of the protein expression level detection of N-cadherin in the cells of the experimental group 1, the control group 1, the TGF-β1 modeling group 1, and the ALA treatment group 1 in Example 1 are shown in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0026] Figure 5 The results of the detection of the expression level of Vimentin in the cells of the experimental group 1, the control group 1, the TGF-β1 modeling group 1, and the ALA treatment group 1 in Example 1 (data are expressed in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0027] Figure 6 The results of the protein expression level detection of α-SMA in the cells of the experimental group 1, the control group 1, the TGF-β1 modeling group 1, and the ALA treatment group 1 in Example 1 are shown in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0028] Figure 7 The results of the protein expression level detection of E-cadherin in the cells of the experimental group 2, the control group 2, the TGF-β1 modeling group 2, and the ALA treatment group 2 in Example 1 are shown in the form of Mean±SEM (n=3), *P<0.05);
[0029] Figure 8 The results of the protein expression level detection of N-cadherin in the cells of the experimental group 2, the control group 2, the TGF-β1 modeling group 2, and the ALA treatment group 2 in Example 1 (data are expressed in the form of Mean±SEM (n=3), *P<0.05);
[0030] Fig. 9 The results of the protein expression level detection of Vimentin in the cells of the experimental group 2, the control group 2, the TGF-β1 modeling group 2, and the ALA treatment group 2 in Example 1 are shown in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0031] Fig.10The results of the protein expression level detection of α-SMA in the cells of the experimental group 2, the control group 2, the TGF-β1 modeling group 2, and the ALA treatment group 2 in Example 1 are shown in the form of Mean±SEM (n=3), **P<0.01);
[0032] Fig.11 The fluorescence intensity detection result of N-cadherin in the cells of experimental groups 1 to 2, control groups 1 to 2, TGF-β1 modeling groups 1 to 2, and ALA treatment groups 1 to 2 in Example 1 (data are expressed in the form of Mean±SEM (n=3), **P<0.01); wherein, Fig.11 A is the immunofluorescence image of N-cadherin in A549 cells. Fig.11 B is the immunofluorescence statistical diagram of N-cadherin in A549 cells. Fig.11 C is the immunofluorescence image of N-cadherin in MLE-12 cells. Fig.11 D in the middle is the immunofluorescence statistical diagram of N-cadherin in MLE-12 cells;
[0033] Fig.12 The figure is a graph showing the cell viability test results of ALA-treated groups 1 to 16 and control groups 1 to 4 in Example 2 (data are expressed in the form of Mean ± SEM (n = 6), *P < 0.05); wherein, Figure 1 Middle A corresponds to ALA-treated groups 1 to 4 and control group 1; Figure 1 Middle B corresponds to 9 to 12 in the ALA-treated group and 3 in the control group; Figure 1 Middle C corresponds to ALA-treated groups 5 to 8 and control group 2; Figure 1 Middle D corresponds to 13 to 16 in the ALA-treated group and 4 in the control group;
[0034] Fig.13 The results of the mRNA expression level detection of the target gene in the experimental groups 1 to 2, the control groups 1 to 2, the TGF-β1 modeling groups 1 to 2, and the ALA treatment groups 1 to 2 in Example 2 (data are expressed in the form of Mean±SEM (n=4), *P<0.05, **P<0.01); wherein, Figure 2 A in the middle corresponds to experimental group 1, control group 1, TGF-β1 modeling group 1, and ALA treatment group 1; Figure 2 B in the middle corresponds to experimental group 2, control group 2, TGF-β1 modeling group 2, and ALA treatment group 2; in the genes of each project, from left to right, they correspond to the control group, TGF-β1 modeling group, ALA treatment group, and experimental group;
[0035] Fig.14The results of the protein expression level detection of Collagen I in the cells of the experimental group 1, the control group 1, the TGF-β1 modeling group 1, and the ALA treatment group 1 in Example 2 (data are expressed in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0036] Fig.15 The results of the protein expression level detection of FN1 in the cells of the experimental group 1, the control group 1, the TGF-β1 modeling group 1, and the ALA treatment group 1 in Example 2 (data are expressed in the form of Mean±SEM (n=3), **P<0.01);
[0037] Fig.16 The results of the protein expression level detection of α-SMA in the cells of the experimental group 1, the control group 1, the TGF-β1 modeling group 1, and the ALA treatment group 1 in Example 2 (data are expressed in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0038] Fig.17 The results of the protein expression level detection of Collagen I in the cells of the experimental group 2, the control group 2, the TGF-β1 modeling group 2, and the ALA treatment group 2 in Example 2 (data are expressed in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0039] Fig.18 The results of the protein expression level detection of FN1 in the cells of the experimental group 2, the control group 2, the TGF-β1 modeling group 2, and the ALA treatment group 2 in Example 2 (data are expressed in the form of Mean±SEM (n=3), **P<0.01);
[0040] Fig.19 The results of the protein expression level detection of α-SMA in the cells of the experimental group 2, the control group 2, the TGF-β1 modeling group 2, and the ALA treatment group 2 in Example 2 (data are expressed in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0041] Fig. 20 The fluorescence intensity detection result of α-SMA in the cells of experimental groups 1 to 2, control groups 1 to 2, TGF-β1 modeling groups 1 to 2, and ALA treatment groups 1 to 2 in Example 2 (data are expressed in the form of Mean±SEM (n=3), **P<0.01); wherein, Fig. 20 A in the middle is the immunofluorescence image of α-SMA in MRC-5 cells. Fig. 20 B is the immunofluorescence statistical diagram of α-SMA in MRC-5 cells. Fig. 20Middle C is the immunofluorescence image of α-SMA in PMLFs cells. Fig. 20 Middle D is the immunofluorescence statistical diagram of α-SMA in PMLFs cells;
[0042] Fig.21 The Fe 2+ The detection results of TNF-α content, ROS content and MDA content (data are expressed in the form of Mean±SEM (n=3), *P<0.05, **P<0.01); Fig.21 A, B and C in the figure are respectively the Fe 2+ content, ROS content and MDA content, Fig.21 D, E and F in the figure are Fe 2+ content, ROS content and MDA content;
[0043] Fig. 22 The results of the protein expression level detection of E-cadherin in the cells of the experimental group 3, the control group 3, the TGF-β1 modeling group 3, and the ALA+TGF-β1 modeling treatment group 3 in Example 3 are shown in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0044] Fig.23 The results of the protein expression level detection of N-cadherin in the cells of the experimental group 3, the control group 3, the TGF-β1 modeling group 3, and the ALA+TGF-β1 modeling treatment group 3 in Example 3 (data are expressed in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0045] Fig.24 The results of the protein expression level detection of Vimentin in the cells of the experimental group 3, the control group 3, the TGF-β1 modeling group 3, and the ALA+TGF-β1 modeling treatment group 3 in Example 3 (data are expressed in the form of Mean±SEM (n=3), **P<0.01);
[0046] Fig.25 The results of the protein expression level detection of Collagen I in the cells of the experimental group 4, the control group 4, the TGF-β1 modeling group 4, and the ALA+TGF-β1 modeling treatment group 4 in Example 3 are shown in the form of Mean±SEM (n=3), **P<0.01);
[0047] Fig.26The results of the protein expression level detection of FN1 in the cells of the experimental group 4, the control group 4, the TGF-β1 modeling group 4, and the ALA+TGF-β1 modeling treatment group 4 in Example 3 are shown (data are expressed in the form of Mean±SEM (n=3), *P<0.05, **P<0.01);
[0048] Fig. 27 This is a graph showing the results of detecting the protein expression level of α-SMA in the cells of the experimental group 4, the control group 4, the TGF-β1 modeling group 4, and the ALA+TGF-β1 modeling treatment group 4 in Example 3 (data are expressed as Mean±SEM (n=3), *P<0.05, **P<0.01). DETAILED DESCRIPTION
[0049] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.
[0050] The following are the detection methods of the relevant indicators in each embodiment:
[0051] Cell viability: After completing cell culture, add 100 μL of CCK-8 diluent (CCK-8 is diluted 10 times with F12K complete medium; the manufacturer of CCK-8 is GlpBio, the product number is GK10001; F12K complete medium is F12K basic medium containing 10 v / v% fetal bovine serum and 1 v / v% double antibody (penicillin-streptomycin mixture); the manufacturer of fetal bovine serum is BDBIO, the product number is F801-500; the manufacturer of double antibody is Biosharp, the product number is BL505A; the manufacturer of F12K basic medium is BDBIO, the product number is L112-500) to each well of the cell culture plate, incubate in a 37°C constant temperature incubator in the dark for 1 h, and then use a multi-function microplate reader (manufacturer is Tecan, model is SPARK) to detect the absorbance at a wavelength of 450 nm.
[0052] The mRNA expression levels of target genes (i.e., E-cadherin, N-cadherin, Vimentin, α-SMA, FN1, COL1-α1, and COL3-α1) in non-control groups (i.e., experimental group, TGF-β1 modeling group, and ALA treatment group) relative to those in the control group were as follows: Total RNA was extracted from the cells using an RNA extraction kit (TransZol Up, manufacturer: TransGen, model: ET111-01-V2) and then cDNA was obtained by reverse transcription using One-Step gDNARemoval and cDNASynthesis SuperMix (manufacturer: TransGen, catalog number: AT311-03), and then RT-PCR was performed using TransScriptUni All-in-One First-Strand cDNASynthesis SuperMix for qPCR One-Step (manufacturer: TransGen, catalog number: AU341-02-v2). After RT-PCR, the data obtained were analyzed using 2 -ΔΔCt The results were statistically analyzed by the method, and the expression level of the internal reference gene β-actin was used for correction. The final value was the mRNA expression level of the target gene in the non-control group relative to that in the control group. In the RT-PCR experiment, the mRNA sequences of human and mouse related genes were found according to the GenBank database on the NCBI website, and the primers corresponding to the target gene were designed through the website. All primers were synthesized by Shanghai Sangon Biotechnology Co., Ltd. The primer sequences are shown in Table 1:
[0053] Table 1 Primer sequences
[0054]
[0055]
[0056] The calculation formula of ΔΔCt is as follows:
[0057] ΔΔCt=(CtTarget-CtReference)X-(CtTarget-CtReference)Control;
[0058] Wherein, ΔΔCt represents the mRNA expression level of the target gene in the non-control group relative to the control group; CtTarget represents the amplification circle number of the target gene (i.e., Ct value); CtReference represents the amplification circle number of β-actin; X represents the cell sample of the non-control group, and Control represents the cell sample of the control group.
[0059] Expression level of target protein (i.e. E-cadherin, N-cadherin, Vimentin, α-SMA, β-actin, Collagen I or FN1) in cells: First, use RIPA lysis buffer (manufacturer: Biosharp, catalog number: BL504A) to extract total protein from cells, and then use BCA kit (manufacturer: GlpBio, catalog number: GK10009) to determine the protein concentration and unify the concentration before adding 5 times the volume of Loading Buffer (manufacturer: TransGen, catalog number: DL101-02), denatured in a 100°C water bath for 10 min, subjected to SDS-PAGE gel electrophoresis and transferred to a PVDF (polyvinylidene fluoride) membrane (manufacturer: Invitrogen, catalog number: 88520), and then incubated in 4% skim milk for 2 h. The PVDF membrane was incubated with the diluted first antibody corresponding to the target protein (diluted in TBST buffer according to the volume ratio in Table 1) at 4°C overnight, and then washed three times with TBST buffer (manufacturer: AMRESCO, catalog number: M235-12.5G-5PK), and the PVDF membrane was incubated with the diluted second antibody (Goat anti-Rabbit IgG (H + L) -HRP, manufacturer: Proteintech, catalog number: SA00013-2, diluted with TBST buffer at a volume ratio of 1:10000) was incubated at 25 ° C for 2 hours, and then the PVDF membrane was placed with the front side facing up in a dark box filled with 6 mL of ECL luminescent liquid (manufacturer: GlpBio, catalog number: GK10008-200), incubated in the dark for 2 minutes, and then the protein gel imaging system (manufacturer: UVP, model: Chemstudio515) was used for image acquisition and protein band analysis; wherein, the information of the diluted first antibody corresponding to the target protein is shown in Table 2:
[0060] Table 2
[0061] Target protein name Antibody Class brand Part Number Dilution ratio E-cadherin Primary Antibody Proteintech 20874-1-AP 1:1000 N-cadherin Primary Antibody Proteintech 22018-1-AP 1:1000 Vimentin Primary Antibody Proteintech 10366-1-AP 1:1000 α-SMA Primary Antibody Proteintech 14395-1-AP 1:2000 β-actin Primary Antibody Proteintech 66009-1-lg 1:10000 Collagen I Primary Antibody Proteintech 14695-1-AP 1:1000 FN1 Primary Antibody Proteintech 15613-1-AP 1:1000
[0062] Fluorescence intensity of target protein (i.e., N-cadherin or α-SMA): first remove the cell culture medium, wash three times with PBS (manufacturer: BDBIO, catalog number: L205-500), discard the waste liquid, add an appropriate amount of 4% paraformaldehyde (manufacturer: Biosharp, catalog number: BL539A), fix at 25°C for 20 min, discard the waste liquid, wash three times with PBS, add 200 μL of 0.5% Triton X-100 (manufacturer: Thermo Scientific, catalog number 28313), permeabilize at 25℃ for 20min, discard the waste liquid, wash with PBS for 3 times, add 500μL 1% goat serum (manufacturer is Zhongshan Jinqiao, catalog number is ZLI-9022), block at 37℃ for 1.5h, discard the blocking solution, wash with PBS for 3 times, add 200μL diluted primary antibody corresponding to the target protein (diluted with TBST buffer according to the volume ratio in Table 3; the manufacturer of TBST buffer is AMRESCO, catalog number is M235-12.5G-5PK), Incubate overnight at 4°C, then wash 3 times with PBS, discard the waste liquid, add 200 μL of diluted second antibody (manufacturer: Thermo, item number: A-11034, diluted with TBST buffer at a volume ratio of 1:500), incubate in a wet box at 25°C in the dark for 1 hour, then wash 3 times with PBS, discard the waste liquid, add 200 μL of DAPI (manufacturer: Beyotime, item number: C1006), incubate at room temperature for 5 minutes, then wash 3 times with PBS, and observe and photograph under a fluorescent inverted microscope (manufacturer: Thermo, model: EVOS M5000); the information of the diluted first antibody corresponding to the target protein is shown in Table 3:
[0063] Table 3
[0064] Target protein name Antibody Class brand Part Number Dilution ratio N-cadherin Primary Antibody Proteintech 22018-1-AP 1:200 α-SMA Primary Antibody Proteintech 14395-1-AP 1:200
[0065] Intracellular Fe 2+ Content: The test was performed according to the instructions of the iron content determination kit (manufacturer: Sigma, catalog number: MAK025-1KT).
[0066] Intracellular ROS (reactive oxygen species) content: detected according to the instructions of the fluorescent probe ROS (manufacturer: Beyotime, product number: S0033).
[0067] Intracellular MDA (malondialdehyde) content: Detection was performed according to the instructions of the MDA detection kit (manufacturer: Solarbio, catalog number: BC0025).
[0068] Example 1
[0069] In order to explore whether ALA can inhibit the transformation of lung epithelial cells to mesenchymal cells, the following steps were performed for verification:
[0070] (1) Preparation of materials;
[0071] F12K complete medium: F12K basal medium containing 10v / v% fetal bovine serum and 1v / v% double antibody; the manufacturer of fetal bovine serum is BDBIO, the product number is F801-500; the manufacturer of double antibody is Biosharp, the product number is BL505A; the manufacturer of F12K basal medium is BDBIO, the product number is L112-500;
[0072] DMEM complete medium: DMEM basal medium containing 10v / v% fetal bovine serum and 1v / v% double antibody; the manufacturer of fetal bovine serum is BDBIO, the product number is F801-500; the manufacturer of double antibody is Biosharp, the product number is BL505A; the manufacturer of DMEM basal medium is BDBIO, the product number is L100-500;
[0073] Human lung epithelial cells A549 (hereinafter referred to as A549 cells): The manufacturer is Beijing Beina Chuanglian Biotechnology Research Institute;
[0074] Mouse lung epithelial cells MLE-12 (hereinafter referred to as MLE-12 cells): The manufacturer is Beijing Beina Chuanglian Biotechnology Research Institute;
[0075] ALA: Manufacturer: Sigma, product number: T5625;
[0076] TGF-β1: manufacturer is PeproTech, product number is 100-21C;
[0077] (2) Cells are grouped and cultured, cell viability is detected, and an appropriate final concentration of ALA is selected for investigation; (In the present invention, the final concentration refers to the final concentration of the target substance added to the culture medium in each well of the cell culture plate.)
[0078] The process of cell group culture is as follows: first, add X cells to Y, culture them in a 37°C constant temperature incubator (the gas composition in the incubator is 95% v / v air and 5% v / v carbon dioxide), and then culture X cells at 1×10 4 The cells were inoculated into a 96-well cell culture plate at a density of cells / well. When the cells grew to 70% confluence, the cell culture medium was replaced with Z and cultured for T. The corresponding X, Y, Z, and T of each group are shown in Tables 4 and 5;
[0079] Table 4
[0080]
[0081] Table 5
[0082]
[0083]
[0084] The results of cell viability test in ALA-treated groups 1 to 16 and control groups 1 to 4 are as follows Figure 1 As shown, from Figure 1 It can be seen that the cell viability of each ALA treatment group is maintained at a close or higher relative level than that of the corresponding control group, which indicates that each ALA treatment group will not be toxic to A549 cells and MLE-12 cells; when the final concentration of ALA is 5μM and 10μM, and after treatment for 48 hours, the cell viability is significantly better than that of the control group, indicating that ALA with a final concentration of 5μM and 10μM has a protective effect on the cell viability of A549 cells and MLE-12 cells. Therefore, both final concentrations of ALA can be used in subsequent explorations (ALA with a final concentration of 10μM is used as an example for subsequent exploration);
[0085] (3) Cells were cultured in groups and the mRNA expression levels of N-cadherin, Vimentin, α-SMA, and E-cadherin in the non-control group relative to the control group, the protein expression levels of N-cadherin, Vimentin, α-SMA, and E-cadherin in the cells of each group, and the fluorescence intensity of N-cadherin in the cells of each group were detected;
[0086] The process of cell group culture is as follows: first, add X cells to Y, culture them in a 37°C constant temperature incubator (the gas composition in the incubator is 95% v / v air and 5% v / v carbon dioxide), and then culture X cells at 5×10 5 The cells were inoculated into a 6-well cell culture plate at a density of 100 cells / well. When the cells grew to 70% confluence, the cell culture medium was replaced with Z and cultured for 48 h. The corresponding X, Y, and Z of each group are shown in Tables 6 and 7.
[0087] Table 6
[0088]
[0089] Table 7
[0090]
[0091] The mRNA expression levels of N-cadherin, Vimentin, α-SMA and E-cadherin in the non-control group relative to the control group are shown in Figure 2 As shown, from Figure 2It can be seen that compared with the control group (the first group from the left), the TGF-β1 modeling group (the second group from the left) significantly increased the mRNA expression levels of N-cadherin, Vimentin, and α-SMA in A549 cells and MLE-12 cells, and reduced the mRNA expression level of E-cadherin in A549 cells and MLE-12 cells; compared with the TGF-β1 modeling group (the second group from the left), the experimental group (the fourth group from the left) significantly reduced the mRNA expression levels of N-cadherin, Vimentin, and α-SMA in A549 cells and MLE-12 cells after ALA treatment, and increased the mRNA expression level of E-cadherin in A549 cells and MLE-12 cells, indicating that ALA significantly inhibited the transformation of lung epithelial cells to mesenchymal cells induced by TGF-β1 at the gene transcription level;
[0092] The protein expression levels of N-cadherin, Vimentin, α-SMA and E-cadherin in cells of each group are shown in Figure 3-Figure 10 As shown, from Figure 3-Figure 10 It can be seen that compared with the control group, the TGF-β1 modeling group significantly increased the protein expression levels of three mesenchymal markers, N-cadherin, Vimentin and α-SMA, in A549 cells and MLE-12 cells, and reduced the protein expression level of epithelial marker E-cadherin; compared with the TGF-β1 modeling group, the experimental group significantly reduced the protein expression levels of three mesenchymal markers, N-cadherin, Vimentin and α-SMA, and increased the protein expression level of epithelial marker E-cadherin after ALA treatment; the fluorescence intensity of N-cadherin in cells of each group is shown in Figure 2. Fig.11 As shown, from Fig.11 It can be seen that compared with the control group, the fluorescence intensity of N-cadherin in A549 cells and MLE-12 cells in the TGF-β1 modeling group was significantly increased; compared with the TGF-β1 modeling group, the fluorescence intensity of N-cadherin in the experimental group was significantly decreased after ALA treatment; the above results indicate that at the protein expression level, ALA significantly inhibited the transformation of lung epithelial cells to mesenchymal cells induced by TGF-β1.
[0093] In summary, ALA significantly inhibited the transformation of lung epithelial cells to mesenchymal cells induced by TGF-β1, both at the gene transcription and protein expression levels, thereby improving the pathological process of TGF-β1-induced pulmonary fibrosis.
[0094] Example 2
[0095] In order to explore whether ALA can inhibit the transformation of lung fibroblasts into myofibroblasts, the following steps were performed for verification:
[0096] (1) Preparation of materials;
[0097] Rat: The manufacturer is Shanghai Slake Laboratory Animal Co., Ltd.
[0098] DMEM basal medium: manufacturer is BDBIO, product number is L100-500;
[0099] Pancreatin: manufacturer is Beyotime, product number is C0201;
[0100] DMEM complete medium: the above-mentioned DMEM basal medium containing 10v / v% fetal bovine serum and 1v / v% double antibody; the manufacturer of fetal bovine serum is BDBIO, the product number is F801-500; the manufacturer of double antibody is Biosharp, the product number is BL505A; the manufacturer of DMEM basal medium is BDBIO, the product number is L100-500;
[0101] PBS: manufacturer is BDBIO, product number is L205-500;
[0102] ALA: Manufacturer: Sigma, product number: T5625;
[0103] TGF-β1: manufacturer is PeproTech, product number is 100-21C;
[0104] Human lung fibroblast MRC-5 (hereinafter referred to as MRC-5 cells): The manufacturer is Beijing Beina Chuanglian Biotechnology Research Institute;
[0105] (2) Isolation and culture of neonatal rat primary lung fibroblasts (PMLFs) (hereinafter referred to as PMLFs cells);
[0106] The isolation and culture process of PMLFs cells is as follows:
[0107] a. Use sterilized ophthalmic surgical scissors to cut open the chest of the suckling mouse under sterile conditions to expose the sternum, carefully remove the lung tissue, and wash the lung tissue in PBS;
[0108] b. Place the washed lung tissue in DMEM basal medium, cut into cube-like small pieces with an edge length of about 3 mm, transfer to a 15 mL centrifuge tube, add trypsin and digest by pipetting to obtain a preliminary digestion solution;
[0109] c. After the initial digestion solution is transferred to a 50 mL centrifuge tube filled with DMEM complete medium, trypsin is added in batches and digestion is repeated by pipetting until the lung tissue pieces in the digestion solution are completely digested to obtain a digestion solution containing PMLFs cells;
[0110] d. Centrifuge the digestion solution containing PMLFs cells at 1500 rpm / min at room temperature for 5 min, and remove the supernatant to obtain PMLFs cell pellet;
[0111] e. Resuspend the PMLFs cell pellet with DMEM complete medium to obtain a PMLFs cell resuspension, transfer the PMLFs cell resuspension to a culture bottle, place it in a 37°C constant temperature incubator (the gas composition in the incubator is 95% v / v air and 5% v / v carbon dioxide) and culture until adherent cells (i.e., PMLFs cells) appear, blow off non-adherent substances with a pipette, replace with fresh DMEM complete medium and continue culturing for later use;
[0112] (3) Cells were grouped and cultured, cell viability was tested, and the appropriate final concentration of ALA was selected for investigation;
[0113] The process of cell grouping culture is as follows: first, X cells are added to DMEM complete medium and cultured in a 37°C constant temperature incubator (the gas composition in the incubator is 95% v / v air and 5% v / v carbon dioxide), and then X cells are cultured at 1×10 4 The cells were inoculated into a 96-well cell culture plate at a density of 100 cells / well. When the cells grew to 70% confluence, the cell culture medium was replaced with Z and cultured for T. The corresponding X, Z, and T of each group are shown in Tables 8 and 9;
[0114] Table 8
[0115]
[0116]
[0117] Table 9
[0118]
[0119] The results of cell viability test in ALA-treated groups 1 to 16 and control groups 1 to 4 are as follows Fig.12 As shown, from Fig.12It can be seen that the cell viability of each ALA treatment group is maintained at a close or higher relative level than that of the corresponding control group, which indicates that each ALA treatment group will not be toxic to MRC-5 cells and PMLFs cells; when the final concentration of ALA is 10μM and after treatment for 48 hours, the cell viability is significantly better than that of the control group, indicating that ALA with a final concentration of 10μM has a protective effect on the cell viability of MRC-5 and PMLFs, so ALA with a final concentration of 10μM was selected for subsequent exploration;
[0120] (4) Cells were grouped and cultured to detect the mRNA expression levels of FN1, COL1-α1, COL3-α1, and α-SMA in the non-control group relative to the control group, the protein expression levels of Collagen I, FN1, and α-SMA in the cells of each group, and the fluorescence intensity of α-SMA in the cells of each group;
[0121] The process of cell grouping culture is as follows: first, X cells are added to DMEM complete medium and cultured in a 37°C constant temperature incubator (the gas composition in the incubator is 95% v / v air and 5% v / v carbon dioxide), and then X cells are cultured at 5×10 5 The cells were inoculated into 6-well cell culture plates at a density of 100 cells / well. When the cells grew to 70% confluence, the cell culture medium was replaced with Z and cultured for 48 h. The corresponding X, Z, and T of each group are shown in Tables 10 and 11;
[0122] Table 10
[0123]
[0124] Table 11
[0125]
[0126] The mRNA expression levels of FN1, COL1-α1, COL3-α1, and α-SMA in the non-control group relative to the control group are shown in Fig.13 As shown, from Fig.13 It can be seen that compared with the control group (the first group from the left), the TGF-β1 modeling group (the second group from the left) significantly increased the mRNA expression levels of FN1, COL1-α1, COL3-α1 and α-SMA in MRC-5 cells and PMLFs cells; compared with the TGF-β1 modeling group (the second group from the left), the experimental group (the fourth group from the left) significantly reduced the mRNA expression levels of COL1-α1, COL3-α1 and α-SMA in MRC-5 cells and PMLFs cells and FN1 in PMLFs cells after ALA treatment, indicating that ALA significantly inhibited the transformation of lung fibroblasts to myofibroblasts induced by TGF-β1 at the gene transcription level;
[0127] The protein expression levels of Collagen I, FN1 and α-SMA in cells of each group are shown in Figure 14-Figure 19 As shown, from Figure 14-Figure 19 It can be seen that compared with the control group, the TGF-β1 modeling group significantly increased the protein expression levels of Collagen I, FN1 and α-SMA in MRC-5 cells and PMLFs cells; compared with the TGF-β1 modeling group, the experimental group significantly reduced the protein expression levels of Collagen I, FN1 and α-SMA in MRC-5 cells and PMLFs cells after ALA treatment; the fluorescence intensity of α-SMA in cells of each group is shown in Fig. 20 As shown, from Fig. 20 It can be seen that compared with the control group, the TGF-β1 modeling group significantly increased the fluorescence intensity of α-SMA in MRC-5 cells and PMLFs cells; compared with the TGF-β1 modeling group, the experimental group significantly reduced the fluorescence intensity of α-SMA in MRC-5 cells and PMLFs cells after ALA treatment; the above results indicate that at the protein expression level, ALA significantly inhibits the TGF-β1-induced transformation of lung fibroblasts to myofibroblasts.
[0128] In summary, ALA significantly inhibited the transformation of lung fibroblasts into myofibroblasts induced by TGF-β1, reduced extracellular matrix deposition, and thus improved the pathological process of TGF-β1-induced pulmonary fibrosis, both at the gene transcription and protein expression levels.
[0129] Example 3
[0130] In order to explore whether ALA inhibits the transformation of lung epithelial cells to mesenchymal cells and the transformation of lung fibroblasts to myofibroblasts by reducing the level of ferroptosis, the following steps were performed for verification:
[0131] (1) Preparation of materials;
[0132] F12K complete medium: F12K basal medium containing 10v / v% fetal bovine serum and 1v / v% double antibody; the manufacturer of fetal bovine serum is BDBIO, the product number is F801-500; the manufacturer of double antibody is Biosharp, the product number is BL505A; the manufacturer of F12K basal medium is BDBIO, the product number is L112-500;
[0133] DMEM complete medium: DMEM basal medium containing 10v / v% fetal bovine serum and 1v / v% double antibody; the manufacturer of fetal bovine serum is BDBIO, the product number is F801-500; the manufacturer of double antibody is Biosharp, the product number is BL505A; the manufacturer of DMEM basal medium is BDBIO, the product number is L100-500;
[0134] A549 cells: The manufacturer is Beijing Beina Chuanglian Biotechnology Research Institute;
[0135] MRC-5 cells: The manufacturer is Beijing Beina Chuanglian Biotechnology Research Institute;
[0136] TGF-β1: manufacturer is PeproTech, product number is 100-21C;
[0137] ALA: Manufacturer: Sigma, product number: T5625;
[0138] Erastin: Manufacturer: GlpBio, Catalog Number: GC16630;
[0139] (2) Cell group culture and detection of Fe 2+ content, ROS (reactive oxygen species) content, MDA (malondialdehyde) content and the expression levels of E-cadherin, N-cadherin, Vimentin, Collagen I, FN1 and α-SMA in cells;
[0140] The process of cell group culture is as follows: first, add X cells to Y, culture them in a 37°C constant temperature incubator (the gas composition in the incubator is 95% v / v air and 5% v / v carbon dioxide), and then culture X cells at 5×10 5 The cells were inoculated into a 6-well cell culture plate at a density of 100 cells / well. When the cells grew to 70% confluence, the cell culture medium was replaced with Z and cultured for 48 hours. The corresponding X, Y, and Z of each group are shown in Table 12, Table 13, Table 14, and Table 15;
[0141] Table 12
[0142]
[0143] Table 13
[0144]
[0145] Table 14
[0146]
[0147] Table 15
[0148]
[0149] Intracellular Fe 2+ The test results of content, ROS content and MDA content are as follows Fig.21 As shown, from Fig.21 It can be seen that compared with the control group, the TGF-β1 modeling group significantly increased the Fe2+ , ROS and MDA content; compared with the TGF-β1 model group, the experimental group significantly reduced Fe 2 + , ROS and MDA content. The above results showed that ALA significantly reduced the level of ferroptosis in lung epithelial cells and lung fibroblasts;
[0150] The protein expression levels of E-cadherin, N-cadherin, Vimentin, Collagen I, FN1, and α-SMA in cells of each group are shown in Figure 2 Figure 22-Figure 27 As shown, from Figure 22-Figure 27 It can be seen that for A549 cells, compared with the control group, the TGF-β1 modeling group significantly increased the expression levels of N-cadherin and Vimentin, two mesenchymal markers, in A549 cells, and reduced the expression level of E-cadherin, an epithelial marker, at the same time; compared with the TGF-β1 modeling group, the ALA+TGF-β1 modeling group significantly reduced the expression levels of N-cadherin and Vimentin after ALA treatment, and increased the expression level of E-cadherin; compared with the ALA+TGF-β1 modeling group, the experimental group significantly increased the expression levels of N-cadherin and Vimentin after adding the ferroptosis inducer Erastin, and reduced the expression level of E-cadherin;
[0151] For MRC-5 cells, compared with the control group, the TGF-β1 modeling group significantly increased the expression levels of three extracellular matrices, Collagen I, FN1 and α-SMA, in MRC-5 cells; compared with the TGF-β1 modeling group, the ALA+TGF-β1 modeling group significantly reduced the expression levels of Collagen I, FN1 and α-SMA after ALA treatment; compared with the ALA+TGF-β1 modeling group, the experimental group significantly increased the expression levels of Collagen I, FN1 and α-SMA after adding the ferroptosis inducer Erastin;
[0152] The above results indicate that the ferroptosis inducer Erastin significantly blocked the inhibitory effect of ALA on TGF-β1-induced transformation of lung epithelial cells to mesenchymal cells and transformation of lung fibroblasts to myofibroblasts.
[0153] In combination with Examples 1 to 3, it can be seen that ALA reduces the level of ferroptosis and thereby reduces the expression levels of three mesenchymal markers, N-cadherin, Vimentin and α-SMA, while increasing the expression level of the epithelial marker E-cadherin, inhibiting the transformation of epithelial cells to mesenchymal cells, and reduces the expression levels of Collagen I, FN1 and α-SMA by reducing the level of ferroptosis, inhibiting the transformation of fibroblasts to myofibroblasts, reducing the deposition of extracellular matrix, and thus slowing down the pathological process of pulmonary fibrosis; the above research results clarify the role and specific mechanism of action of ALA in the progression of pulmonary fibrosis, and provide a new theoretical basis and drug research direction for the prevention and treatment of pulmonary fibrosis.
[0154]
[0155]
[0156]
[0157]
[0158]
[0159]
[0160]
[0161]
Claims
1. The use of α-lipoic acid in the preparation of a drug for treating pulmonary fibrosis, characterized in that: Pulmonary fibrosis is TGF-β1-induced pulmonary fibrosis.
2. The use of α-lipoic acid according to claim 1 in preparing a drug for treating pulmonary fibrosis, characterized in that: TGF-β1-induced pulmonary fibrosis involves the transformation of lung epithelial cells to mesenchymal cells and the transformation of lung fibroblasts to myofibroblasts.
3. The use of α-lipoic acid according to claim 2 in the preparation of a drug for treating pulmonary fibrosis, characterized in that: Lung epithelial cells were human lung epithelial cells A549 or mouse lung epithelial cells MLE-12; lung fibroblasts were human lung fibroblasts MRC-5 or neonatal rat primary lung fibroblasts PMLFs.
4. The use of α-lipoic acid in the preparation of a drug for treating pulmonary fibrosis according to claim 2, characterized in that: α-Lipoic acid inhibits the transformation of lung epithelial cells to mesenchymal cells and the transformation of lung fibroblasts to myofibroblasts by reducing the level of ferroptosis.
